Jason Murata
Partner
Jason Murata, Chair of Axinn's Diversity, Equity & Inclusion Committee, draws on over 20 years of experience to address clients' most critical intellectual property challenges. With a strong background in pre-trial, trial, and appellate litigation, he adeptly handles complex IP disputes across a wide range of industries, including pharmaceuticals, biopharmaceuticals, technology, consumer goods, and food products. His extensive litigation background also equips him to navigate critical issues relating to managing clients’ IP risks and freedom to operate. Law360 has recognized Jason as a “Legal Lion” for his skill in arguing before the Federal Circuit on behalf of his clients.
Jason Murata
Partner
Jason Murata, Chair of Axinn's Diversity, Equity & Inclusion Committee, draws on over 20 years of experience to address clients' most critical intellectual property challenges. With a strong background in pre-trial, trial, and appellate litigation, he adeptly handles complex IP disputes across a wide range of industries, including pharmaceuticals, biopharmaceuticals, technology, consumer goods, and food products. His extensive litigation background also equips him to navigate critical issues relating to managing clients’ IP risks and freedom to operate. Law360 has recognized Jason as a “Legal Lion” for his skill in arguing before the Federal Circuit on behalf of his clients.
In addition to his active IP practice, Jason is a recognized leader in advancing diversity, equity, and inclusion within the IP community. Along with chairing Axinn's DEI Committee, he co-founded and chairs the American Intellectual Property Law Association (AIPLA)’s DE&I Task Force and is regularly invited to speak on DEI-related topics, including at the DEIA Colloquium co-hosted by AIPLA, IPIC, and ASIPI. Jason has also chaired the Intellectual Property Law Institute at the LGBTQ+ Bar Association’s Lavender Law® Conference and Career Fair on multiple occasions and previously led the AIPLA IP Practice in Japan Committee.
In his pro bono practice, Jason has successfully represented prisoners in cases pertaining to violations of the U.S. Constitution’s Equal Protection Clause.
Experience
-
Mayne Pharma Int’l Pty Ltd. v. Merck & Co., Inc., No. 15-cv-00438 (D. Del.) (patent infringement action relating to Merck’s Noxafil posaconazole products)
- Globus Medical, Inc. v. DePuy Synthes Products, LLC, No. 13-cv-00854 (D. Del.) (defend patent infringement action relating to spinal fusion implants)
-
Otsuka Pharmaceutical Co., Ltd. v. Zydus Pharmaceuticals USA Inc., Nos. 14-cv-03158-JBS-KMW & 14-cv-07252-JBS-KMW (D.N.J.) (obtained denial of motion for temporary restraining order in patent infringement action relating to generic aripiprazole drug product (Abilify))
-
Pfizer, Inc. v. Tiger Pharmaceuticals, LLC, No. 14-cv-01501-AJT-TRJ (E.D. Va.); Pfizer, Inc. v. Tiger Pharmaceuticals, LLC, No. 14-cv-08958-GHW (S.D.N.Y.); Johnson Matthey Inc. v. Pfizer, Inc., 2:15-cv-00014-AWA-TEM (E.D. Va.) (obtained dismissal of patent infringement action relating to dofetilide drug product within four months of filing of the action)
-
Depomed, Inc. v. Actavis Elizabeth LLC, No. 3:12-cv-01358 (D.N.J.) and Appeal No. 14-1828 (Fed. Cir.) (bench trial in patent infringement action relating to generic once-daily gabapentin product)
-
The Procter & Gamble Co. v. Conopco, Inc., No. 13-CV-00732-TSB (S.D. Ohio) (represented Unilever in patent infringement action relating to antidandruff shampoo products)
-
Brandeis University v. Unilever United States, Inc., No. 12-cv-01510 (N.D. Ill.) (Posner, J.) (represented Unilever in patent infringement action brought by marketer of SmartBalance products relating to margarines and buttery spreads)
-
Hospira, Inc. v. Sun Pharmaceutical Industries, Inc., No. 2:10-cv-14514 (BAF/MJH) (E.D. Mich.) (defense of patent infringement action relating to generic dexemdetomidine drug product)
- Tyco Healthcare Group LP, et al. v Mutual Pharmaceutical Co., Inc., et al., Civil Action No. 07-cv-1299 (D.N.J.) and Appeal No. 2010-1513 (Fed. Cir.) (obtained summary judgment of invalidity that asserted patent was obvious, which was affirmed by Federal Circuit)
- In re Gabapentin Patent Litigation, MDL No. 1384, Master Civil Action No. 00-2931 (D.N.J.) (patent infringement dispute involving gabapentin)
- Aventis Pharmaceuticals Inc., et al. v. Sun Pharma Global Inc., et al., Civil Action Nos. 09-cv-00325 & -05179; Civil Action No.: 2:09-cv-5179-JAG (D.N.J.) (patent infringement dispute involving fexofenadine and fexofenadine / pseudoephedrine products)
- Roche Palo Alto LLC. v. Endo Pharmaceuticals Inc., Civil Action No. 10-cv-00261-GMS (D. Del.) (patent infringement dispute involving valganciclovir hydrochloride)
- United States Gypsum Co. v. Lafarge North America, Inc., Lafarge S.A., et al., Civil Action No. 03-CV-6027 (N.D. Ill. 2003) (theft of confidential, proprietary and trade secret information and patent infringement involving gypsum drywall manufacturing)
- Pall Corp. v. Entegris, Inc., Civil Action No. 07-CV-1869 (E.D.N.Y. 2007) (infringement dispute concerning filter media packing and capsule design)
- Pall Corp. v. Entegris, Inc., Civil Action No. 05-CV-5894 (E.D.N.Y. 2005) (patent infringement dispute involving filter assembly methods and pre-wet packaging)
- Entegris, Inc. v. Pall Corp., Appeal Nos. 2004-1440, 2005-1265, -1266, 2006-1374 (Fed. Cir. 2006) (appeal from preliminary injunction and contempt order in patent infringement dispute concerning filter assembly)
- AstraZeneca AB, et al. v. Mutual Pharmaceutical Co., Inc., Appeal No. 04-1100 (Fed. Cir. 2004) (appeal in pharmaceutical case relating to generic extended-release felodipine tablets)
- Ciba Specialty Chemicals Corp. v. Zinkan Enterprises Inc., et al., Civil Action No. C2 03 174 (S.D. Ohio 2002) (patent infringement dispute involving treatment of wastewater from coal mining)
Honors
- Lawdragon, 500 Leading Litigators in America (2025)
- World Intellectual Property Review Leaders (2024)
- World Intellectual Property Review Diversity Champion (2024)
-
American Intellectual Property Law Association, Diversity Champion (2024)
- Profiles in Diversity Journal Asian Leadership Award Winner (2023)
- New Leaders in the Law – Connecticut Law Tribune (2014)
Education
- JD – Washington University School of Law (2002)
- MA, Biology – Washington University (2002)
- BS, Biochemistry – McMaster University (1999)
Admissions
- California
- Connecticut
- Illinois
- New York
- U.S. Court of Appeals for the Federal Circuit
- U.S. District Court Northern District of Illinois
- U.S. District Court Northern District of California
Quotes
Their knowledge of the industry, law, and implications is deep and thoughtful. The quality of the work...is first-rate.
Chambers USA
Their performance and service is outstanding. They are extremely responsive, give good explanations and keep you up to date.
Chambers USA
News & Insights
News & Insights
Jason Murata Named a Profiles in Diversity Journal Diverse Lawyers Making a Difference Award Winner
Awards & Recognitions
Intellectual Property
LSPN North America Fall Conference 2024
Speaking Engagement
Intellectual Property
ACI 4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
Speaking Engagement
Intellectual Property
Jason Murata Named a 2024 Diversity Champion Award Recipient by the American Intellectual Property Law Association
Awards & Recognitions
Intellectual Property
Axinn Partners Named to Lawdragon 500 Leading Litigators in America 2025
Awards & Recognitions
Antitrust
Axinn Attorneys Named to WIPR Leaders and WIPR Diversity's Top 100 Lists for 2024
Awards & Recognitions
Intellectual Property
ACI Summit on Biosimilars and Innovator Biologics 2024
Speaking Engagement
Intellectual Property
Protecting Trade Secrets in the Face of FTC's Ban of Non-Compete Clauses
Byline Articles
Antitrust
Jason Murata Named to World Intellectual Property Review's Diversity in IP listings 2024
Awards & Recognitions
Intellectual Property
Axinn Assists Pro Bono Client with Obtaining Settlement of Civil Rights Claims
Pro Bono